Henry Schein (HSIC) has drawn fresh attention after announcing a planned reduction in its Board of Directors in 2026, including the retirement of long-serving director Stanley M. Bergman after 44 years.

The recent Board changes come after a year where Henry Schein delivered a 22.33% total shareholder return, while the 3 year total shareholder return of a 6.67% decline and 5 year total shareholder return of 7.08% show more muted progress. This suggests momentum has strengthened over the last year.

If this kind of governance shift has you thinking about where else leadership decisions might matter, it could be a good time to scan for other opportunities using the 19 top founder-led companies

With the shares at US$77.42, and an indicated intrinsic value gap plus a 16% discount to analyst targets, the key question is whether Henry Schein is still mispriced or if the market already reflects its future growth.

Most Popular Narrative: 13.2% Undervalued

Henry Schein's most followed narrative suggests a fair value of about $89.23 per share versus the last close at $77.42, which frames the current price as meaningfully below that estimate.

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments, supporting structurally higher gross margins and likely driving earnings expansion.

Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention. This positions Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.

Want to see what sits behind that margin story, the expected shift in segment mix, and the earnings multiple this narrative leans on? The full valuation sets out how revenue, profitability and future P/E assumptions combine to reach that fair value number.

Result: Fair Value of $89.23 (UNDERVALUED)

However, this relies on smoother execution than the risks suggest, with pricing pressure in core categories and ongoing staffing shortages both capable of undermining that earnings path.

Next Steps

If the combination of optimism and caution in this story leaves you unsure, take a closer look at the numbers and decide for yourself with 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Henry Schein has sharpened your focus, do not stop here. Use the screener to spot fresh ideas that match your risk, income, and quality preferences.

• Target resilient income by scanning for companies in the 11 dividend fortresses that might help anchor the yield side of your portfolio.
• Hunt for quality at a discount by checking the 60 high quality undervalued stocks and see which names currently trade below their implied worth.
• Prioritise capital preservation first by reviewing the 72 resilient stocks with low risk scores and focus on businesses with more robust overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.